Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.

C Porta, A Levy, R Hawkins, D Castellano, J Bellmunt, P Nathan, R McDermott, J Wagstaff, P Donnellan, J McCaffrey, F Vekeman, MP Neary, J Diaz, F Mehmud, MS Duh

    Research output: Contribution to journalArticlepeer-review

    Original languageEnglish
    Pages (from-to)1517-1526
    Number of pages9
    JournalCancer Medicine
    Issue number6
    Publication statusPublished - Dec 2014

    Cite this